[go: up one dir, main page]

WO2010070677A3 - A process for the preparation of prasugrel and its pharmaceutically acceptable salts thereof - Google Patents

A process for the preparation of prasugrel and its pharmaceutically acceptable salts thereof Download PDF

Info

Publication number
WO2010070677A3
WO2010070677A3 PCT/IN2009/000714 IN2009000714W WO2010070677A3 WO 2010070677 A3 WO2010070677 A3 WO 2010070677A3 IN 2009000714 W IN2009000714 W IN 2009000714W WO 2010070677 A3 WO2010070677 A3 WO 2010070677A3
Authority
WO
WIPO (PCT)
Prior art keywords
prasugrel
pharmaceutically acceptable
preparation
acceptable salts
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2009/000714
Other languages
French (fr)
Other versions
WO2010070677A2 (en
Inventor
Khan Mubeen Ahmed
Srinivas Reddy Sanikommu
Bhaskar Rao Antyakula Pydi
Shankar Sanganabhatla
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glenmark Generics Ltd
Original Assignee
Glenmark Generics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Generics Ltd filed Critical Glenmark Generics Ltd
Publication of WO2010070677A2 publication Critical patent/WO2010070677A2/en
Publication of WO2010070677A3 publication Critical patent/WO2010070677A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

The present invention relates to processes for the preparation of prasugrel and its pharmaceutically acceptable salts, including novel crystalline forms of prasugrel hydrochloride, and pharmaceutical compositions thereof. The present invention also relates to solid state properties of prasugrel or a pharmaceutically acceptable salt thereof.
PCT/IN2009/000714 2008-12-15 2009-12-09 A process for the preparation of prasugrel and its pharmaceutically acceptable salts thereof Ceased WO2010070677A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
IN2609MU2008 2008-12-15
IN2609/MUM/2008 2008-12-15
IN343MU2009 2009-02-17
IN343/MUM/2009 2009-02-17
IN1248/MUM/2009 2009-05-14
IN1248MU2009 2009-05-14

Publications (2)

Publication Number Publication Date
WO2010070677A2 WO2010070677A2 (en) 2010-06-24
WO2010070677A3 true WO2010070677A3 (en) 2011-02-24

Family

ID=42269188

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2009/000714 Ceased WO2010070677A2 (en) 2008-12-15 2009-12-09 A process for the preparation of prasugrel and its pharmaceutically acceptable salts thereof

Country Status (1)

Country Link
WO (1) WO2010070677A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2469883A (en) * 2009-04-30 2010-11-03 Sandoz Ag Novel crystalline form of Prasugrel hydrogensulphate
DE102009036646A1 (en) 2009-08-07 2011-02-10 Ratiopharm Gmbh Prasugrel in non-crystalline form and pharmaceutical composition thereof
EP2883877A1 (en) 2010-04-08 2015-06-17 Teva Pharmaceutical Industries, Ltd. Crystalline forms of prasugrel salts
WO2012023145A2 (en) * 2010-08-18 2012-02-23 Hetero Research Foundation Prasugrel hydrochloride crystalline particles
CN102838618A (en) 2011-06-22 2012-12-26 广东东阳光药业有限公司 A method for preparing prasugrel and new crystal form of prasugrel hydrochloride
US8603537B2 (en) 2012-04-02 2013-12-10 Egis Pharmaceuticals Plc Prasugrel containing quickly released stable oral pharmaceutical compositions
PL402028A1 (en) 2012-12-12 2014-06-23 Instytut Farmaceutyczny Method for preparing polymorph B form of Prasugrel hydrochloride in pharmaceutical grade
CN103610674B (en) * 2013-12-09 2015-01-07 海南灵康制药有限公司 Solid preparation containing micronized prasugrel
CN117619352B (en) * 2024-01-26 2024-04-09 中国科学院合肥物质科学研究院 A degradation agent for perfluorinated compounds and its use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0542411A2 (en) * 1991-09-09 1993-05-19 Sankyo Company Limited Tetrahydrothienopyridine derivatives, furo and pyrrolo analogs thereof and their preparation and uses for inhibiting blood platelet aggregation
EP0785205A1 (en) * 1994-10-07 1997-07-23 Ube Industries, Ltd. 2-silyloxytetrahydrothienopyridine, salt thereof, and process for producing the same
WO2007114526A1 (en) * 2006-04-06 2007-10-11 Daiichi Sankyo Company, Limited Process for producing high-purity prasugrel and acid addition salt thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0542411A2 (en) * 1991-09-09 1993-05-19 Sankyo Company Limited Tetrahydrothienopyridine derivatives, furo and pyrrolo analogs thereof and their preparation and uses for inhibiting blood platelet aggregation
EP0785205A1 (en) * 1994-10-07 1997-07-23 Ube Industries, Ltd. 2-silyloxytetrahydrothienopyridine, salt thereof, and process for producing the same
WO2007114526A1 (en) * 2006-04-06 2007-10-11 Daiichi Sankyo Company, Limited Process for producing high-purity prasugrel and acid addition salt thereof

Also Published As

Publication number Publication date
WO2010070677A2 (en) 2010-06-24

Similar Documents

Publication Publication Date Title
WO2009066326A3 (en) Improved process for the preparation of prasugrel and its pharmaceutically acceptable salts
WO2010070677A3 (en) A process for the preparation of prasugrel and its pharmaceutically acceptable salts thereof
WO2010092090A3 (en) Novel salts of sitagliptin
WO2011042918A3 (en) Improved processes for preparing prasugrel and pharmaceutically acceptable salts thereof
WO2009084024A3 (en) A process for the preparation of r-sit agliptin and its pharmaceutically acceptable salts thereof
WO2009062044A3 (en) Processes for the preparation of prasugrel, and its salts and polymorphs
WO2009085990A3 (en) Processes for the preparation of sitagliptin and pharmaceutically acceptable salts thereof
WO2010001257A3 (en) Novel solid state forms of laquinimod and its sodium salt
WO2011048604A3 (en) Processes for the preparation of darunavir and the amorphous form thereof
WO2008001195A3 (en) Novel processes for the preparation of dpp iv inhibitors
WO2012070062A3 (en) Novel polymorph of nilotinib hydrochloride
WO2011009938A3 (en) Stambomycin and derivatives, their production and their use as drugs
WO2011157722A3 (en) Solid ivabradine-containing composition
WO2008129501A3 (en) Pharmaceutical compositions of duloxetine
WO2010070449A3 (en) Highly pure laquinimod or a pharmaceutically acceptable salt thereof
WO2010049449A3 (en) Novel salts of sunitinib
WO2008001201A3 (en) Pharmaceutical compositions of clopidogrel
WO2011021864A3 (en) Novel compound for complementing anticancer drugs, a production method for the same, a composition for complementing anticancer drugs comprising the same, and a method for reducing resistance to anticancer drugs using the same
IN2012DN04868A (en)
WO2010129636A3 (en) Lenalidomide polymorph
WO2010012459A3 (en) A process for the preparation of solifenacin salts and their inclusion into pharmaceutical dosage forms
WO2008034912A3 (en) Process for the synthesis of clopidogrel and new forms of pharmaceutically acceptable salts thereof
WO2010079045A3 (en) Crystalline salt forms of flibanserine
WO2011008666A3 (en) 3-phenoxymethylpyrrolidine compounds
WO2010046932A3 (en) Extended release pharmaceutical composition of minocycline and process thereof

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09833086

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 09833086

Country of ref document: EP

Kind code of ref document: A2